

CURRENT REPORT

**SOLOS ENDOSCOPY, INC.
OTCPK: SNDY**

ENTRY OR TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT; CHANGES IN CONTROL OF ISSUER.

Under a Securities Purchase Agreement (“Agreement”), dated May 25, 2017, Robert Segersten and Marie Segersten, his wife, the persons then in control of the Company, sold 50,228,310 shares of the Company’s common stock and 518,464 shares of the Company’s Series B convertible preferred stock (397,100 shares from Robert Segersten and 121,364 shares from Marie Segersten), such preferred stock representing the majority control of the Company, to American Medical Group LLC (“Purchaser”). This sale was done in return for the Purchaser’s promissory note (“Note”) in the principal amount of \$7,500 plus interest from the date of issue at an annual rate of 1.5%, payable to Mr. Segersten on demand at any time after May 25, 2018. In the event the Purchaser fails to pay the Note when due, Mr. Segersten has the option at his sole discretion of either (i) cancelling the Agreement and the Note and receiving the return the subject securities of the Company or (ii) giving the Purchaser 45 days to perform its obligations under the Note.

DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL CERTAIN OFFICERS.

Under the Agreement, the Company entered in a Mutual Release and Separation Agreement with Mr. Segersten dated May 25, 2017 under which Mr. Segersten resigned as a director, and president and chief executive officer, of the Company. In addition, the Company elected Dom L. Gatto, the beneficial owner of the Purchaser and a former director of the Company (from 2006 to 2009), a director of the Company and the Company’s president and chief executive officer. In addition, as of June 28, 2017, the Company entered into a long-term employment agreement with Mr. Gatto for him to serve on a full-time basis as president and chief executive officer through December 31, 2022, and to receive compensation of \$13,500 per month through December 31, 2017, and thereafter an annual salary of \$250,000.

Mr. Gatto, age 56, he is the founder of AMG Development, LLC, a medical device-consulting firm, and has served as an executive consultant for this firm from 2005 to the present. His professional experience ranges from product management to executive management for over ten start-up entities. He founded MedTrek, an innovative surgical company that partnered with Olympus worldwide. He was later chief operating officer for start-up Acueity Healthcare, a revolutionary technology for early detection of breast cancer featured in Time magazine as one of the top five medical technologies for breast cancer detection and treatment. Since Acueity, he has been an executive advisor to startup entities, including Acclarent, Inc. (recently acquired by Johnson & Johnson).

During his career, Mr. Gatto has developed, launched and successfully managed over 75 medical devices, ranging from polymer-based disposables to integrated imaging systems. He holds seven patents and is co-inventor on three patent pending medical devices. Mr. Gatto graduated Magna Cum Laude with a B.S. degree in Marketing from Quinnipiac University and attended the Executive Management program at the John E. Anderson School of Business – UCLA. He is currently an Entrepreneur in Residence at The University of Notre Dame’s Mendoza School of Business for entrepreneurial studies.

SIGNATURE

The Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Solos Endoscopy, Inc.

Dated: Oct. 17, 2017

By: /s/ Dom L. Gatto
Dom L. Gatto, President